Alliance Pharmaceuticals Limited Risk Report

🛡️ Financial & Liquidity

Alliance Pharmaceuticals has been involved in significant financial transactions involving acquisitions and take-private deals. The company agreed to a substantial buyout valued at £362 million by its largest shareholder in 2025. This represents a significant move indicating strong interest from investors and potential changes in the company’s operational strategies.

• Alliance Pharmaceuticals agreed to a £362 million acquisition by its biggest shareholder on 🗓 March 10, 2025.
• On 🗓 January 10, 2025, Alliance Pharma accepted a £349.7 million buyout offer from its largest investor.
• The takeover was approved through shareholder approval on 🗓 March 17, 2025, confirming investors’ confidence in the transaction.
• On 🗓 May 14, 2025, the company’s £362 million buyout in a take-private deal was completed.
• Alliance Pharmaceuticals announced another major financing event on 🗓 January 14, 2025, with White & Case advising PIK creditors on acquisition financing.

⚖️ Legal & Regulatory

Alliance Pharmaceuticals has confronted and successfully contested legal challenges related to anti-competitive practices. After an initial ruling imposing fines, the company successfully appealed, overturning a significant £35 million penalty. This reflects the company's resilience and ability to mitigate legal risks.

• On 🗓 August 30, 2024, the CMA will not appeal after the 'pay for delay' fines were overturned.
• The tribunal reversed a ruling against pharmaceutical directors on 🗓 May 31, 2024.
• On 🗓 May 23, 2024, Alliance Pharma won a UK court appeal against fines related to anti-nausea drugs.
• The tribunal overturned the earlier ruling on 🗓 May 28, 2024, stating 'material errors' in the initial case.
• Firms, including Alliance, were fined for illegal arrangements with the NHS on 🗓 February 3, 2022.

🏗️ Operational & Business Continuity

Alliance Pharmaceuticals has been proactive in maintaining business continuity through strategic acquisitions and operational adjustments. Despite delays in releasing financial results, the company remains on track with its growth strategies, securing steady results amidst acquisitions and executive changes.

• On 🗓 April 7, 2025, Alliance Pharma reported steady results for 2024 and announced a significant acquisition.
• There was a delay in releasing the 2023 financial results as stated on 🗓 April 5, 2024.
• Alliance Pharma acquired a US scar treatment brand on 🗓 July 10, 2024, as part of strategic growth.
• The company's COO stepped down, with the position disestablished on 🗓 July 23, 2024.